Mirion Technologies, Inc. MIR
We take great care to ensure that the data presented and summarized in this overview for Mirion Technologies, Inc. is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Top Institutions Holding MIR
View all-
Goldman Sachs Group Inc New York, NY34.8MShares$649 Million0.06% of portfolio
-
Vanguard Group Inc Valley Forge, PA23.7MShares$442 Million0.0% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD20.2MShares$376 Million0.13% of portfolio
-
Black Rock Inc. New York, NY15.8MShares$295 Million0.0% of portfolio
-
Swedbank Ab Stockholm, V710.2MShares$191 Million0.15% of portfolio
-
Janus Henderson Group PLC London, X08.1MShares$151 Million0.05% of portfolio
-
Alyeska Investment Group, L.P. Chicago, IL7.82MShares$146 Million0.48% of portfolio
-
Dimensional Fund Advisors LP Austin, TX7.01MShares$131 Million0.02% of portfolio
-
State Street Corp Boston, MA5.37MShares$100 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA4.5MShares$84 Million0.0% of portfolio
Latest Institutional Activity in MIR
Top Purchases
Top Sells
About MIR
Mirion Technologies, Inc. provides radiation detection, measurement, analysis, and monitoring products and services in the United States, Canada, the United Kingdom, France, Germany, Finland, China, Belgium, Netherlands, Estonia, and Japan. It operates through two segments, Medical and Industrial. The medical segment offers radiation oncology quality assurance and dosimetry solutions; patient safety solutions for diagnostic imaging and radiation therapy centers; radiation therapy quality assurance solutions for calibrating and verifying imaging and treatment accuracy; and radionuclide therapy products for nuclear medicine applications, such as shielding, product handling, medical imaging furniture, and rehabilitation products. This segment supports applications in medical diagnostics, cancer treatment, practitioner safety, and rehabilitation. The Industrial segment focuses on addressing critical radiation safety, measurement, and analysis applications; and provides personal radiation detection, identification equipment, and analysis tools. The company's products and solutions also include nuclear medicines, dosimeters, contamination and clearance monitors, reactor instrumentation and control equipment and systems, medical and industrial imaging systems and related accessories, alpha spectroscopy instruments, alpha/beta counting instruments, and gamma spectroscopy detector systems; and electrical penetration, cancer diagnostics, software, and other services. It serves hospitals, clinics and urgent care facilities, dental and veterinary offices, radiation treatment facilities, OEMs for radiation therapy, laboratories, military organizations, government agencies, industrial companies, power and utility companies, reactor design firms, and NPPs. The company was formerly known as Global Monitoring Systems, Inc. and changed its name to Mirion Technologies, Inc. in January 2006. Mirion Technologies, Inc. was incorporated in 2005 and is headquartered in Atlanta, Georgia.
Insider Transactions at MIR
Insider Transaction List
View allDate | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Dec 17
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
2,400,000
+37.76%
|
-
|
Dec 17
2024
|
Brian Schopfer Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
525,000
+36.94%
|
-
|
Dec 13
2024
|
Loic Eloy Technologies Group President |
SELL
Open market or private sale
|
Direct |
44,000
-24.77%
|
$748,000
$17.89 P/Share
|
Dec 13
2024
|
John W Kuo Director |
SELL
Bona fide gift
|
Direct |
8,300
-11.51%
|
-
|
Nov 12
2024
|
Brian Schopfer Chief Financial Officer |
BUY
Conversion of derivative security
|
Direct |
175,000
+32.03%
|
-
|
Nov 12
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Conversion of derivative security
|
Direct |
800,000
+33.96%
|
-
|
Nov 12
2024
|
Lawrence D Kingsley Director |
BUY
Bona fide gift
|
Indirect |
1,050,000
+20.0%
|
-
|
Nov 12
2024
|
Lawrence D Kingsley Director |
SELL
Bona fide gift
|
Direct |
1,050,000
-95.17%
|
-
|
Nov 12
2024
|
Lawrence D Kingsley Director |
BUY
Conversion of derivative security
|
Direct |
1,050,000
+48.76%
|
-
|
Nov 05
2024
|
Lawrence D Kingsley Director |
SELL
Bona fide gift
|
Direct |
3,150,000
-98.34%
|
-
|
Nov 04
2024
|
Lawrence D Kingsley Director |
BUY
Conversion of derivative security
|
Direct |
3,150,000
+49.58%
|
-
|
Oct 31
2024
|
Emmanuelle Lee Chief Legal Officer |
SELL
Open market or private sale
|
Indirect |
3,405
-100.0%
|
$47,670
$14.27 P/Share
|
Oct 31
2024
|
Emmanuelle Lee Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
3,405
+50.0%
|
-
|
Oct 31
2024
|
Emmanuelle Lee Chief Legal Officer |
SELL
Conversion of derivative security
|
Indirect |
3,405
-9.42%
|
-
|
Oct 24
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
7,500
-100.0%
|
$105,000
$14.11 P/Share
|
Oct 24
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
7,500
+50.0%
|
-
|
Oct 24
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Conversion of derivative security
|
Indirect |
7,500
-0.29%
|
-
|
Sep 24
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Open market or private sale
|
Indirect |
7,500
-100.0%
|
$75,000
$10.47 P/Share
|
Sep 24
2024
|
Thomas D Logan Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Indirect |
7,500
+50.0%
|
-
|
Sep 24
2024
|
Thomas D Logan Chief Executive Officer |
SELL
Conversion of derivative security
|
Indirect |
7,500
-0.29%
|
-
|
Last 12 Months Summary
Grant, award, or other acquisition | 553K shares |
---|---|
Conversion of derivative security | 8.1M shares |
Bona fide gift | 1.05M shares |
Other acquisition or disposition | 1.77M shares |
Bona fide gift | 4.21M shares |
---|---|
Sale (or disposition) back to the issuer | 90.9K shares |
Payment of exercise price or tax liability | 140K shares |
Open market or private sale | 239K shares |
Conversion of derivative security | 73.4K shares |